Cidofovir: Difference between revisions

Revision as of 17:54, 11 September 2020

Active against essentially all DNA viruses, including polyomaviruses (BK virus, JC virus), human papillomavirus, adenovirus, all of the human herpesviruses, poxviruses (including monkeypox virus and variola virus)
Not active against hepatitis B virus or RNA viruses

Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid

@@ Line 1: / Line 1: @@
+== Background ==
-* Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]]
-* Should be given with [[probenecid]] 2 g IV prior to each dose
+*Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]]
+*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}
+=== Spectrum of Activity ===
+* Active against essentially all DNA viruses, including polyomaviruses ([[BK virus]], [[JC virus]]), [[human papillomavirus]], [[adenovirus]], all of the [[human herpesviruses]], poxviruses (including [[monkeypox virus]] and [[variola virus]])
+* Not active against h[[Hepatitis B virus|epatitis B virus]] or [[:Category:RNA viruses|RNA viruses]]
+=== Pharmacokinetics and Pharmacodynamics ===
 * Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97
-* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}
+== Dosing ==
-* Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by probenecid
+*Should be given with [[probenecid]] 2 g IV prior to each dose
+== Safety ==
+*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]]
 [[Category:Antivirals]]